Evaluation of Neuroinduced Mesenchymal Stem Cells and Mesenchymal Stem Cell-Derived Exosomes in Patients With Parkinsonism

Starting soon · Phase 2

Conditions studied: Parkinsonism or Parkinson's Disease Nos, Parkinsonism in Diseases Classified Elsewhere

In brief

This clinical trial investigates the safety and therapeutic potential of mesenchymal stem cell-based therapies in patients with parkinsonism. The study evaluates neuroinduced mesenchymal stem cells and mesenchymal stem cell-derived exosomes as potential regenerative treatments targeting neurodegeneration within dopaminergic pathways.

Key facts

Study ID

NCT07471230

Run by

Biocells Medical

People needed

120

Starts

2026-11-23

Expected to finish

2029-11-23

Last updated by the study team

2026-03-13

Who can join

Age: 48 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 40-80 years Clinical diagnosis of Parkinsonism Hoehn and Yahr stage II-III Stable pharmacological treatment for ≥3 months

You may not qualify if…

• Atypical parkinsonian syndromes unrelated to neurodegeneration History of malignancy within 5 years Severe cardiovascular disease Prior cellular therapy Active infection or immunosuppression

Where it is running

• Neuropostep — Warsaw, Poland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.